



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

# PRODUCT INFORMATION



## SARS-CoV-2 nsp7 (recombinant)


Item No. 40881

### Overview and Properties

<b>Synonyms:</b>	SARS-CoV-2 Non-structural Protein 7, Severe Acute Respiratory Syndrome Coronavirus 2 nsp7
<b>Source:</b>	Recombinant SARS-CoV-2 C-terminal His-tagged nsp7 expressed in <i>E. coli</i>
<b>Amino Acids:</b>	3,831-3,913
<b>Uniprot No.:</b>	PODTD1
<b>Storage:</b>	-80°C (as supplied); avoid repeated freeze/thaw cycles
<b>Stability:</b>	≥1 year
<b>Purity:</b>	≥90%
<b>Supplied in:</b>	50 mM Tris-HCl, pH 7.5, with 200 mM sodium chloride and 20% glycerol
<b>Endotoxin Testing:</b>	< 1.0 EU/μg, determined by the LAL endotoxin assay
<b>Protein Concentration:</b>	<i>batch specific</i> mg/ml

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Image



Lane 1: MW Markers  
Lane 2: SARS-CoV-2 nsp7 (2 μg)  
Lane 3: SARS-CoV-2 nsp7 (10 μg)

SDS-PAGE Analysis of SARS-CoV-2 nsp7

WARNING  
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA  
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY  
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/01/2024

CAYMAN CHEMICAL  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM

# PRODUCT INFORMATION



## Description

---

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive-stranded RNA virus and the causative agent of COVID-19, a primarily respiratory illness characterized by fever, cough, and shortness of breath that can lead to life-threatening complications.<sup>1-5</sup> The SARS-CoV-2 genome contains approximately 30 kilobases and 14 open reading frames (ORFs) that encode four structural proteins: spike, envelope, membrane, and nucleocapsid, as well as 16 non-structural proteins and 9 accessory factors.<sup>6</sup> SARS-CoV-2 non-structural protein 7 (nsp7) is encoded within *ORF1ab* and is a cofactor in the RNA replication transcriptional complex. nsp7 is highly conserved in coronaviruses, and in SARS-CoV-2 it forms a decameric RNA replication transcriptional complex with the RNA polymerase cofactor nsp8 and the RNA-dependent RNA polymerase (RdRp) nsp12.<sup>7</sup> Mutations in the nsp7-nsp8 binding interface reduce the stability of the RNA replication transcriptional complex, leading to impaired RNA polymerase activity.<sup>8</sup>

## References

---

1. Kandeel, M., Ibrahim, A., Fayez, M., *et al.* From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. *J. Med. Virol.* **92(6)**, 660-666 (2020).
2. Lu, R., Zhao, X., Li, J., *et al.* Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. *Lancet* **395(10224)**, 565-574 (2020).
3. Meo, S.A., Alhowikan, A.M., Al-Khlaiwi, T., *et al.* Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. *Eur. Rev. Med. Pharmacol. Sci.* **24(4)**, 2012-2019 (2020).
4. Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., *et al.* Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb. Res.* **191**, 145-147 (2020).
5. Yang, F., Shi, S., Zhu, J., *et al.* Analysis of 92 deceased patients with COVID-19. *J. Med. Virol.* **92(11)**, 2511-2515 (2020).
6. Romano, M., Ruggiero, A., Squeglia, F., *et al.* A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. *Cells* **9(5)**, 1267 (2020).
7. Wang, Q., Wu, J., Wang, H., *et al.* Structural basis for RNA replication by the SARS-CoV-2 polymerase. *Cell* **182(2)**, 417-428 (2020).
8. Biswal, M., Diggs, S., Xu, D., *et al.* Two conserved oligomer interfaces of NSP7 and NSP8 underpin the dynamic assembly of SARS-CoV-2 RdRP. *Nucleic Acids Res.* **49(10)**, 5956-5966 (2021).

CAYMAN CHEMICAL  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM